Which has higher earnings and valuation, ALMS or KRYS?

Krystal Biotech has higher revenue and earnings than Alumis. Alumis is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Alumis $24.05M 110.96 -$243.32M -$1.98 N/A Krystal Biotech $389.13M 24.36 $204.83M $7.48 42.99

Is ALMS or KRYS more profitable?

Krystal Biotech has a net margin of 53.92% compared to Alumis' net margin of -2,825.70%. Krystal Biotech's return on equity of 19.25% beat Alumis' return on equity. Company Net Margins Return on Equity Return on Assets Alumis -2,825.70% -88.79% -70.72% Krystal Biotech 53.92% 19.25% 17.62%

Does the media favor ALMS or KRYS?

In the previous week, Krystal Biotech had 9 more articles in the media than Alumis. MarketBeat recorded 11 mentions for Krystal Biotech and 2 mentions for Alumis. Krystal Biotech's average media sentiment score of 1.20 beat Alumis' score of 0.94 indicating that Krystal Biotech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alumis 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Krystal Biotech 8 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings & valuation, ALMS or CYTK?

Alumis has higher earnings, but lower revenue than Cytokinetics. Alumis is trading at a lower price-to-earnings ratio than Cytokinetics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Alumis $24.05M 110.96 -$243.32M -$1.98 N/A Cytokinetics $88.04M 97.90 -$784.96M -$6.84 N/A

Is ALMS or CYTK more profitable?

Cytokinetics has a net margin of -784.02% compared to Alumis' net margin of -2,825.70%. Cytokinetics' return on equity of 0.00% beat Alumis' return on equity. Company Net Margins Return on Equity Return on Assets Alumis -2,825.70% -88.79% -70.72% Cytokinetics -784.02% N/A -52.86%

Does the media prefer ALMS or CYTK?

In the previous week, Cytokinetics had 9 more articles in the media than Alumis. MarketBeat recorded 11 mentions for Cytokinetics and 2 mentions for Alumis. Alumis' average media sentiment score of 0.94 beat Cytokinetics' score of 0.63 indicating that Alumis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alumis 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cytokinetics 4 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation & earnings, ABVX or ALMS?

Alumis has higher revenue and earnings than Abivax. Abivax is trading at a lower price-to-earnings ratio than Alumis, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Abivax N/A N/A -$380.27M -$5.21 N/A Alumis $24.05M 110.96 -$243.32M -$1.98 N/A

Is ABVX or ALMS more profitable?

Abivax has a net margin of 0.00% compared to Alumis' net margin of -2,825.70%. Alumis' return on equity of -88.79% beat Abivax's return on equity. Company Net Margins Return on Equity Return on Assets Abivax N/A -99.02% -70.26% Alumis -2,825.70% -88.79% -70.72%

Does the media prefer ABVX or ALMS?

In the previous week, Abivax had 8 more articles in the media than Alumis. MarketBeat recorded 10 mentions for Abivax and 2 mentions for Alumis. Alumis' average media sentiment score of 0.94 beat Abivax's score of 0.24 indicating that Alumis is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Abivax 1 Very Positive mention(s) 1 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Alumis 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation & earnings, QGEN or ALMS?

Qiagen has higher revenue and earnings than Alumis. Alumis is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Qiagen $2.09B 3.69 $424.88M $1.91 19.57 Alumis $24.05M 110.96 -$243.32M -$1.98 N/A

Is QGEN or ALMS more profitable?

Qiagen has a net margin of 19.16% compared to Alumis' net margin of -2,825.70%. Qiagen's return on equity of 14.40% beat Alumis' return on equity. Company Net Margins Return on Equity Return on Assets Qiagen 19.16% 14.40% 8.40% Alumis -2,825.70% -88.79% -70.72%

Does the media prefer QGEN or ALMS?

In the previous week, Qiagen and Qiagen both had 2 articles in the media. Alumis' average media sentiment score of 0.94 beat Qiagen's score of 0.90 indicating that Alumis is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Qiagen 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Alumis 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings & valuation, ALMS or IBRX?

Alumis has higher earnings, but lower revenue than ImmunityBio. Alumis is trading at a lower price-to-earnings ratio than ImmunityBio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Alumis $24.05M 110.96 -$243.32M -$1.98 N/A ImmunityBio $113.29M 66.56 -$351.40M -$0.85 N/A

Is ALMS or IBRX more profitable?

ImmunityBio has a net margin of -606.15% compared to Alumis' net margin of -2,825.70%. ImmunityBio's return on equity of 0.00% beat Alumis' return on equity. Company Net Margins Return on Equity Return on Assets Alumis -2,825.70% -88.79% -70.72% ImmunityBio -606.15% N/A -59.53%

Does the media favor ALMS or IBRX?

In the previous week, ImmunityBio had 5 more articles in the media than Alumis. MarketBeat recorded 7 mentions for ImmunityBio and 2 mentions for Alumis. Alumis' average media sentiment score of 0.94 beat ImmunityBio's score of 0.44 indicating that Alumis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alumis 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ImmunityBio 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Alumis (ALMS) Competitors

$20.93 +0.87 (+4.35%)

Closing price 03:59 PM Eastern

Extended Trading

$20.61 -0.32 (-1.53%)

As of 07:40 PM Eastern

Compare

ALMS vs. KRYS, CYTK, ABVX, QGEN, and IBRX

Should you buy Alumis stock or one of its competitors? MarketBeat compares Alumis with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Alumis include Krystal Biotech (KRYS), Cytokinetics (CYTK), Abivax (ABVX), Qiagen (QGEN), and ImmunityBio (IBRX). These companies are all part of the "pharmaceutical products" industry.

How does Alumis compare to Krystal Biotech?

Alumis (NASDAQ:ALMS) and Krystal Biotech (NASDAQ:KRYS) are both mid-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, earnings, media sentiment, analyst recommendations, risk, dividends, institutional ownership and profitability.

In the previous week, Krystal Biotech had 9 more articles in the media than Alumis. MarketBeat recorded 11 mentions for Krystal Biotech and 2 mentions for Alumis. Krystal Biotech's average media sentiment score of 1.20 beat Alumis' score of 0.94 indicating that Krystal Biotech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alumis	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Krystal Biotech	8 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Alumis currently has a consensus target price of $40.30, suggesting a potential upside of 92.53%. Krystal Biotech has a consensus target price of $324.11, suggesting a potential upside of 0.80%. Given Alumis' higher probable upside, equities research analysts plainly believe Alumis is more favorable than Krystal Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alumis	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83
Krystal Biotech	0 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.83

Krystal Biotech has higher revenue and earnings than Alumis. Alumis is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alumis	$24.05M	110.96	-$243.32M	-$1.98	N/A
Krystal Biotech	$389.13M	24.36	$204.83M	$7.48	42.99

Alumis has a beta of -0.56, meaning that its share price is 156% less volatile than the broader market. Comparatively, Krystal Biotech has a beta of 0.53, meaning that its share price is 47% less volatile than the broader market.

86.3% of Krystal Biotech shares are held by institutional investors. 33.7% of Alumis shares are held by insiders. Comparatively, 13.1% of Krystal Biotech shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Krystal Biotech has a net margin of 53.92% compared to Alumis' net margin of -2,825.70%. Krystal Biotech's return on equity of 19.25% beat Alumis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alumis	-2,825.70%	-88.79%	-70.72%
Krystal Biotech	53.92%	19.25%	17.62%

Summary

Krystal Biotech beats Alumis on 12 of the 16 factors compared between the two stocks.

How does Alumis compare to Cytokinetics?

Alumis (NASDAQ:ALMS) and Cytokinetics (NASDAQ:CYTK) are both mid-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, dividends, risk, profitability, analyst recommendations, media sentiment and institutional ownership.

Cytokinetics has a net margin of -784.02% compared to Alumis' net margin of -2,825.70%. Cytokinetics' return on equity of 0.00% beat Alumis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alumis	-2,825.70%	-88.79%	-70.72%
Cytokinetics	-784.02%	N/A	-52.86%

Alumis currently has a consensus price target of $40.30, indicating a potential upside of 92.53%. Cytokinetics has a consensus price target of $99.30, indicating a potential upside of 43.35%. Given Alumis' higher possible upside, equities research analysts clearly believe Alumis is more favorable than Cytokinetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alumis	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83
Cytokinetics	1 Sell rating(s)	3 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	2.86

Alumis has a beta of -0.56, indicating that its share price is 156% less volatile than the broader market. Comparatively, Cytokinetics has a beta of 0.42, indicating that its share price is 58% less volatile than the broader market.

In the previous week, Cytokinetics had 9 more articles in the media than Alumis. MarketBeat recorded 11 mentions for Cytokinetics and 2 mentions for Alumis. Alumis' average media sentiment score of 0.94 beat Cytokinetics' score of 0.63 indicating that Alumis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alumis	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cytokinetics	4 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Alumis has higher earnings, but lower revenue than Cytokinetics. Alumis is trading at a lower price-to-earnings ratio than Cytokinetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alumis	$24.05M	110.96	-$243.32M	-$1.98	N/A
Cytokinetics	$88.04M	97.90	-$784.96M	-$6.84	N/A

Summary

Cytokinetics beats Alumis on 10 of the 15 factors compared between the two stocks.

How does Alumis compare to Abivax?

Abivax (NASDAQ:ABVX) and Alumis (NASDAQ:ALMS) are both mid-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, analyst recommendations, risk, dividends, media sentiment and valuation.

Abivax has a net margin of 0.00% compared to Alumis' net margin of -2,825.70%. Alumis' return on equity of -88.79% beat Abivax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Abivax	N/A	-99.02%	-70.26%
Alumis	-2,825.70%	-88.79%	-70.72%

Alumis has higher revenue and earnings than Abivax. Abivax is trading at a lower price-to-earnings ratio than Alumis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abivax	N/A	N/A	-$380.27M	-$5.21	N/A
Alumis	$24.05M	110.96	-$243.32M	-$1.98	N/A

Abivax has a beta of 0.69, indicating that its share price is 31% less volatile than the broader market. Comparatively, Alumis has a beta of -0.56, indicating that its share price is 156% less volatile than the broader market.

Abivax currently has a consensus target price of $130.08, indicating a potential upside of 28.96%. Alumis has a consensus target price of $40.30, indicating a potential upside of 92.53%. Given Alumis' stronger consensus rating and higher probable upside, analysts clearly believe Alumis is more favorable than Abivax.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abivax	1 Sell rating(s)	2 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.73
Alumis	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83

In the previous week, Abivax had 8 more articles in the media than Alumis. MarketBeat recorded 10 mentions for Abivax and 2 mentions for Alumis. Alumis' average media sentiment score of 0.94 beat Abivax's score of 0.24 indicating that Alumis is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Abivax	1 Very Positive mention(s)	1 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Alumis	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

47.9% of Abivax shares are held by institutional investors. 33.7% of Alumis shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Alumis beats Abivax on 10 of the 16 factors compared between the two stocks.

How does Alumis compare to Qiagen?

Qiagen (NYSE:QGEN) and Alumis (NASDAQ:ALMS) are both mid-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, analyst recommendations, risk, dividends, media sentiment and valuation.

Qiagen has higher revenue and earnings than Alumis. Alumis is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Qiagen	$2.09B	3.69	$424.88M	$1.91	19.57
Alumis	$24.05M	110.96	-$243.32M	-$1.98	N/A

Qiagen has a net margin of 19.16% compared to Alumis' net margin of -2,825.70%. Qiagen's return on equity of 14.40% beat Alumis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Qiagen	19.16%	14.40%	8.40%
Alumis	-2,825.70%	-88.79%	-70.72%

Qiagen has a beta of 0.66, indicating that its share price is 34% less volatile than the broader market. Comparatively, Alumis has a beta of -0.56, indicating that its share price is 156% less volatile than the broader market.

Qiagen currently has a consensus target price of $44.98, indicating a potential upside of 20.32%. Alumis has a consensus target price of $40.30, indicating a potential upside of 92.53%. Given Alumis' stronger consensus rating and higher probable upside, analysts clearly believe Alumis is more favorable than Qiagen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Qiagen	1 Sell rating(s)	6 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.42
Alumis	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83

70.0% of Qiagen shares are held by institutional investors. 9.0% of Qiagen shares are held by company insiders. Comparatively, 33.7% of Alumis shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Qiagen and Qiagen both had 2 articles in the media. Alumis' average media sentiment score of 0.94 beat Qiagen's score of 0.90 indicating that Alumis is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Qiagen	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Alumis	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Qiagen beats Alumis on 9 of the 15 factors compared between the two stocks.

How does Alumis compare to ImmunityBio?

Alumis (NASDAQ:ALMS) and ImmunityBio (NASDAQ:IBRX) are both mid-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, profitability, media sentiment, analyst recommendations, valuation, dividends, risk and institutional ownership.

Alumis presently has a consensus target price of $40.30, suggesting a potential upside of 92.53%. ImmunityBio has a consensus target price of $14.20, suggesting a potential upside of 97.22%. Given ImmunityBio's higher possible upside, analysts plainly believe ImmunityBio is more favorable than Alumis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alumis	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83
ImmunityBio	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

ImmunityBio has a net margin of -606.15% compared to Alumis' net margin of -2,825.70%. ImmunityBio's return on equity of 0.00% beat Alumis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alumis	-2,825.70%	-88.79%	-70.72%
ImmunityBio	-606.15%	N/A	-59.53%

Alumis has higher earnings, but lower revenue than ImmunityBio. Alumis is trading at a lower price-to-earnings ratio than ImmunityBio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alumis	$24.05M	110.96	-$243.32M	-$1.98	N/A
ImmunityBio	$113.29M	66.56	-$351.40M	-$0.85	N/A

Alumis has a beta of -0.56, meaning that its share price is 156% less volatile than the broader market. Comparatively, ImmunityBio has a beta of 0.03, meaning that its share price is 97% less volatile than the broader market.

In the previous week, ImmunityBio had 5 more articles in the media than Alumis. MarketBeat recorded 7 mentions for ImmunityBio and 2 mentions for Alumis. Alumis' average media sentiment score of 0.94 beat ImmunityBio's score of 0.44 indicating that Alumis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alumis	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ImmunityBio	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

8.6% of ImmunityBio shares are owned by institutional investors. 33.7% of Alumis shares are owned by insiders. Comparatively, 69.5% of ImmunityBio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

ImmunityBio beats Alumis on 11 of the 17 factors compared between the two stocks.

Get Alumis News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ALMS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ALMS vs. The Competition

Export

Metric	Alumis	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$2.56B	$3.29B	$6.47B	$11.73B
Dividend Yield	N/A	2.33%	2.67%	5.56%
P/E Ratio	-10.57	19.62	24.43	24.09
Price / Sales	110.96	301.53	503.66	108.37
Price / Cash	N/A	120.36	43.20	54.62
Price / Book	7.27	8.21	10.50	6.82
Net Income	-$243.32M	$23.89M	$3.56B	$337.41M
7 Day Performance	2.66%	-3.00%	-2.02%	-0.96%
1 Month Performance	-11.53%	-1.64%	0.66%	1.68%
1 Year Performance	536.23%	40.20%	21.85%	26.88%

Alumis Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ALMS Alumis	3.2851 of 5 stars	$20.93 +4.3%	$40.30 +92.5%	+497.0%	$2.56B	$24.05M	N/A	N/A
KRYS Krystal Biotech	2.6406 of 5 stars	$301.00 -2.2%	$324.11 +7.7%	+126.0%	$9.07B	$389.13M	40.24	210	Positive News
CYTK Cytokinetics	3.296 of 5 stars	$71.48 -1.1%	$99.30 +38.9%	+94.2%	$9.00B	$88.04M	N/A	250	Insider Trade Options Volume
ABVX Abivax	3.2769 of 5 stars	$101.53 -3.2%	$130.08 +28.1%	+1,145.6%	$8.36B	N/A	N/A	61
QGEN Qiagen	4.603 of 5 stars	$36.69 -2.3%	$44.98 +22.6%	-23.9%	$7.74B	$2.09B	19.16	5,654	Short Interest Decrease

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ALMS) was last updated on 6/11/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Alumis (ALMS) Competitors

ALMS vs. KRYS, CYTK, ABVX, QGEN, and IBRX

How does Alumis compare to Krystal Biotech?

Summary

How does Alumis compare to Cytokinetics?

Summary

How does Alumis compare to Abivax?

Summary

How does Alumis compare to Qiagen?

Summary

How does Alumis compare to ImmunityBio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALMS vs. The Competition

Alumis Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Alumis (ALMS) Competitors

ALMS vs. KRYS, CYTK, ABVX, QGEN, and IBRX

How does Alumis compare to Krystal Biotech?

Does the media favor ALMS or KRYS?

Do analysts prefer ALMS or KRYS?

Which has higher earnings and valuation, ALMS or KRYS?

Which has more risk and volatility, ALMS or KRYS?

Do institutionals and insiders believe in ALMS or KRYS?

Is ALMS or KRYS more profitable?

Summary

How does Alumis compare to Cytokinetics?

Is ALMS or CYTK more profitable?

Do analysts prefer ALMS or CYTK?

Which has more volatility and risk, ALMS or CYTK?

Does the media prefer ALMS or CYTK?

Which has preferable earnings & valuation, ALMS or CYTK?

Summary

How does Alumis compare to Abivax?

Is ABVX or ALMS more profitable?

Which has higher valuation & earnings, ABVX or ALMS?

Which has more volatility & risk, ABVX or ALMS?

Do analysts prefer ABVX or ALMS?

Does the media prefer ABVX or ALMS?

Do institutionals & insiders believe in ABVX or ALMS?

Summary

How does Alumis compare to Qiagen?

Which has higher valuation & earnings, QGEN or ALMS?

Is QGEN or ALMS more profitable?

Which has more volatility & risk, QGEN or ALMS?

Do analysts prefer QGEN or ALMS?

Do institutionals & insiders believe in QGEN or ALMS?

Does the media prefer QGEN or ALMS?

Summary

How does Alumis compare to ImmunityBio?

Do analysts prefer ALMS or IBRX?

Is ALMS or IBRX more profitable?

Which has higher earnings & valuation, ALMS or IBRX?

Which has more volatility and risk, ALMS or IBRX?

Does the media favor ALMS or IBRX?

Do insiders and institutionals have more ownership in ALMS or IBRX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALMS vs. The Competition

Alumis Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools